Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

被引:22
|
作者
Vena, Gino A. [1 ]
Cassano, Nicoletta [1 ]
Coco, Valeria [2 ]
De Simone, Clara [2 ]
机构
[1] Univ Bari, Dept Biomed Sci & Human Oncol, Unit Dermatol & Venereol, I-70124 Bari, Italy
[2] Univ Cattolica Sacro Cuore, Unit Dermatol, I-00168 Rome, Italy
关键词
Antihypertensive drugs; cutaneous adverse drug reactions; drug-induced dermatitis; eczema; hydrochlorothiazide; CAPTOPRIL; DRUG; SURVEILLANCE; BRADYKININ; IRBESARTAN; ERUPTION;
D O I
10.3109/08923973.2013.797992
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cutaneous adverse drug reactions (ADRs) to antihypertensive drugs have been frequently reported. We describe a peculiar clinical pattern of cutaneous ADR, represented by an eczematous reaction induced by certain antihypertensive drugs that we observed in elderly patients. The case series consisted of 23 hypertensive patients aged 66-87 years; 19 of them were taking another drug in addition to the suspected antihypertensive medication and 15 were on polytherapy with three or more drugs to treat multiple comorbidities. The antihypertensive culprit agents were angiotensin-converting enzyme (ACE) inhibitors in 9 patients, ACE-inhibitors combined to hydrochlorothiazide (HCT) in 7 subjects, angiotensin II receptor blockers alone in 2 patients and associated with HCT in 5 cases. The cutaneous ADR was characterized by an eczematous rash that was generalized in 16 patients and localized in 7 cases, with predominant involvement of lower limbs. Such lesions developed after a latency of 4-30 months and were associated with moderate-to-severe itch, usually unresponsive to oral antihistamines. Histopathological diagnosis was available for 9 cases, confirming the presence of a spongiotic dermatitis with possible associated psoriasiform skin changes.
引用
收藏
页码:447 / 450
页数:4
相关论文
共 50 条
  • [1] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk
    Potier, Louis
    Roussel, Ronan
    Elbez, Yedid
    Marre, Michel
    Zeymer, Uwe
    Reid, Christopher M.
    Ohman, Magnus
    Eagle, Kim A.
    Bhatt, Deepak L.
    Steg, Philippe Gabriel
    HEART, 2017, 103 (17) : 1339 - 1346
  • [2] Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
    Douillard, Marie
    Deheb, Zineb
    Bozon, Agathe
    Raison-Peyron, Nadia
    Dereure, Olivier
    Moulis, Lionel
    Soria, Angele
    Du-Thanh, Aurelie
    WORLD ALLERGY ORGANIZATION JOURNAL, 2023, 16 (08):
  • [3] Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction
    Evans, Marie
    Carrero, Juan-Jesus
    Szummer, Karolina
    Akerblom, Axel
    Edfors, Robert
    Spaak, Jonas
    Jacobson, Stefan H.
    Andell, Pontus
    Lindhagen, Lars
    Jernberg, Tomas
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (14) : 1687 - 1697
  • [4] Angiotensin-receptor blockers in prevention of cardiovascular events: are they as effective as angiotensin-converting enzyme inhibitors?
    Teo, Koon K.
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2009, 119 (1-2): : 8 - 10
  • [5] Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers
    Elliott W.J.
    Current Hypertension Reports, 2000, 2 (4) : 402 - 411
  • [6] Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure
    Chitnis, Abhishek S.
    Aparasu, Rajender R.
    Chen, Hua
    Kunik, Mark E.
    Schulz, Paul E.
    Johnson, Michael L.
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2016, 31 (05): : 395 - 404
  • [7] Angioedema due to angiotensin-converting enzyme inhibitors
    Agostoni, A
    Cicardi, M
    Cugno, M
    Zingale, LC
    Gioffré, D
    Nussberger, J
    IMMUNOPHARMACOLOGY, 1999, 44 (1-2): : 21 - 25
  • [8] Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?
    Mao, Yeqing
    Xu, Xin
    Wang, Xiao
    Zheng, Xiangyi
    Xie, Liping
    ONCOTARGET, 2016, 7 (06) : 6765 - 6773
  • [9] Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users
    de Jong, Hilda J. I.
    Vandebriel, Rob J.
    Saldi, Siti R. F.
    van Dijk, Liset
    van Loveren, Henk
    Tervaert, Jan Willem Cohen
    Klungel, Olaf H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (08) : 835 - 843
  • [10] Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension
    Kuan, Yi-Chun
    Huang, Kuang-Wei
    Yen, Der-Jen
    Hu, Chaur-Jong
    Lin, Cheng-Li
    Kao, Chia-Hung
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 220 : 462 - 466